What is Zacks Research’s Forecast for BMY FY2026 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Zacks Research upped their FY2026 EPS estimates for Bristol Myers Squibb in a research report issued on Thursday, August 13th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $6.85 per share for the year, up from their prior estimate of $6.27. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2028 earnings at $5.11 EPS.

A number of other research firms have also recently issued reports on BMY. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Cantor Fitzgerald reiterated a “neutral” rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating for the company. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Bank of America cut their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Price Performance

BMY opened at $64.71 on Monday. The stock has a market cap of $132.18 billion, a P/E ratio of 14.25, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.10. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a fifty day simple moving average of $59.75 and a 200 day simple moving average of $59.06.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Institutional Trading of Bristol Myers Squibb

A number of large investors have recently added to or reduced their stakes in the company. Bank OZK bought a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $474,000. Old North State Trust LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $725,000. Caitlin John LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $220,000. Equitable Holdings Inc. acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $7,303,000. Finally, Centaurus Financial Inc. acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $637,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.